Summary results: slope of the fitted regression line for the prevalence of concomitant psychotropic treatment in year before and after first use of memantine, 2005–2011
| Memantine cohort | AChEI cohort | |||||
|---|---|---|---|---|---|---|
| Slope 12 months before | Slope 12 months after | Slope difference (95% CI) | Slope 12 months before | Slope 12 months after | Slope difference (95% CI) | |
| Antipsychotics | 0.69 | −0.22 | 0.91 (0.73 to 1.09) | 0.36 | 0.13 | 0.23 (0.20 to 0.26) |
| Atypical antipsychotics | 0.60 | −0.19 | 0.79 (0.62 to 0.96) | 0.30 | 0.10 | 0.20 (0.18 to 0.23) |
| Typical antipsychotics | 0.12 | −0.09 | 0.21 (0.12 to 0.30) | 0.06 | 0.03 | 0.04 (0.02 to 0.05) |
| Antidepressants | 0.56 | −0.02 | 0.58 (0.38 to 0.79) | 0.47 | 0.27 | 0.19 (0.14 to 0.24) |
| Tricyclic antidepressants | 0.05 | −0.17 | 0.22 (0.13 to 0.31) | 0.00 | 0.03 | −0.04 (−0.06 to −0.01) |
| SSRI | 0.33 | 0.01 | 0.33 (0.15 to 0.50) | 0.34 | 0.15 | 0.20 (0.16 to 0.24) |
| Other antidepressants | 0.22 | 0.06 | 0.16 (0.04 to 0.28) | 0.17 | 0.10 | 0.07 (0.05 to 0.09) |
| Anxiolytics | 0.22 | −0.12 | 0.34 (0.21 to 0.48) | 0.06 | 0.01 | 0.04 (0.02 to 0.06) |
| Hypnotics | 0.16 | −0.26 | 0.42 (0.26 to 0.59) | 0.11 | 0.00 | 0.11 (0.08 to 0.14) |
AChEI, acetylcholinesterase inhibitors.